What’s inside
View ResearchDelve into the promising study of CAR/CXCR5-T cell immunotherapy for sustained remission of SIV infection in rhesus macaques. This innovative approach involves genetically modifying T cells to express an SIV-specific chimeric antigen receptor (CAR) and the follicular homing receptor CXCR5. The research demonstrates that these engineered T cells can home to lymphoid follicles, effectively target viral RNA+ cells, and reduce viral loads without significant adverse effects, suggesting potential for future HIV treatments.
CAR/CXCR5-T Cell Immunotherapy for SIV
Study shows CAR/CXCR5-T cell therapy is safe and potentially effective in promoting sustained remission of SIV in rhesus macaques.
Targeting Lymphoid Follicles with CAR/CXCR5-T Cells
CAR/CXCR5-T cells successfully target SIV-infected cells in lymphoid follicles, reducing viral replication.
Proliferation of CAR/CXCR5-T Cells in Vivo
Infused CAR/CXCR5-T cells proliferate in lymphoid tissues, showing sustained presence and activity against SIV.
Safety and Efficacy of CAR/CXCR5-T Cell Treatment
Study demonstrates safety and potential efficacy of CAR/CXCR5-T cells in reducing SIV viral loads in treated macaques.
Long-Term Remission with CAR/CXCR5-T Cells
CAR/CXCR5-T cell therapy shows promise for long-term control of SIV without ART, with reduced viral loads and persistence.
Mechanisms of CAR/CXCR5-T Cell Activity
CAR/CXCR5-T cells home to lymphoid follicles, contact SIV-infected cells, and reduce follicular viral RNA levels.
.svg)
.jpg)
.webp)
